Management of Suicidal Ideation and Self‑Harm in Adolescents

Immediate Safety Measures

Remove all lethal means from the home (e.g., firearms—the most common method of adolescent suicide in the United States—and all medications) and secure or dispose of them under adult supervision. Guideline recommendation (strong) 2
Establish continuous third‑party monitoring by a responsible adult until a psychiatric evaluation is completed. Guideline recommendation (strong) 2
Arrange an urgent psychiatric evaluation within 24–48 hours to determine need for hospitalization based on high‑risk indicators (explicit intent to die, persistent wish to die, abnormal mental state, prior attempts, or lack of family commitment). Guideline recommendation (strong) 2

Dialectical Behavior Therapy for Adolescents (DBT‑A) shows the greatest promise for reducing both the absolute repetition and frequency of self‑harm in youth, although it requires intensive resources and experienced clinicians. Evidence level: moderate‑quality systematic review 1
Cognitive‑behavioral therapy specifically focused on suicide prevention should be offered to lower suicidal ideation in patients with a history of self‑directed violence. Evidence level: moderate‑quality randomized trials 4
Greater family involvement in treatment reduces medication non‑adherence and improves overall outcomes; the degree of involvement should be individualized to the adolescent’s preferences. Evidence level: moderate 1

Pharmacologic agents are not recommended solely for the purpose of preventing self‑harm or suicide in adolescents. Guideline recommendation (strong) 6
If major depressive disorder is diagnosed, selective serotonin reuptake inhibitors (SSRIs) are first‑line; fluoxetine is the only SSRI approved by the FDA for adolescents ≥ 8 years. Guideline recommendation (moderate) 3
Intensive monitoring is mandatory during the first 4–6 weeks of SSRI therapy, with weekly visits to assess for emergent suicidal ideation, behavioral activation, or akathisia. Guideline recommendation (strong) 3
The absolute risk of SSRI‑induced suicidal ideation is low (≈ 1 % with treatment vs 0.2 % with placebo; Number Needed to Harm = 143), while the Number Needed to Treat for clinical response is ≈ 3. Evidence level: pooled data from controlled trials 3

Lithium should be considered only if a bipolar spectrum disorder is diagnosed, as it is first‑line for bipolar disorder with suicidal features based on adult data showing marked reductions in suicide attempts and completed suicides. Evidence level: adult randomized and observational studies 2
The 2024 VA/DoD guidelines downgraded lithium from “weak for” to insufficient evidence for reducing suicide or suicide attempts even in adults with mood disorders. Guideline recommendation (insufficient) 4
No published trials evaluate lithium for suicide prevention specifically in adolescents. Evidence gap 1

The treating clinician must be reachable outside scheduled therapeutic hours or have adequate on‑call coverage, and must have experience managing suicidal crises. Guideline recommendation (strong) 2
All prescribed medications must be dispensed and monitored by a third party who can control dosing and promptly report any behavioral changes. Guideline recommendation (strong) 2
After each self‑harm episode, a comprehensive therapeutic assessment should be performed to develop a formulation that addresses concurrent disorders (e.g., depression, eating disorders) and contributing psychosocial factors. Guideline recommendation (moderate) 1

Do not rely on “no‑suicide contracts”; their efficacy is unproven and they should not lead clinicians or families to relax vigilance. Guideline recommendation (strong) 2
Do not prescribe tricyclic antidepressants as first‑line treatment because of their high lethality in overdose and lack of proven benefit in adolescents. Guideline recommendation (strong) 2
Do not prescribe benzodiazepines or phenobarbital, as they may increase disinhibition or impulsivity. Guideline recommendation (strong) 2